CERE News and Press, Ceres Inc. From 10/20/21

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2021 financial results and pipeline updates o...

Live webcast today from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will host a virtual R&D event...

Current Chief Accounting Officer Mark Bodenrader named as interim CFO Search underway for permanent successor CAMBRIDGE, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat...

Shares of Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) traded at a new 52-week high today of $38.10. Approximately 9 million shares have changed hands today, as compared to an average 30-day volume of 588,000 shares. Cerevel Therapeutics Holdings Inc is dedicated to unraveling the my...

Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophrenia Live webcast scheduled for Thursday, Oct. 7 from 10:00 to 11:30 a.m. ET ...

Shares of Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) traded today at $36.40, eclipsing its 52-week high. So far today approximately 9 million shares have been exchanged, as compared to an average 30-day volume of 582,000 shares. Cerevel Therapeutics Holdings Inc is dedicated to unr...

Shares of Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) traded today at $32.22, eclipsing its 52-week high. Approximately 9 million shares have changed hands today, as compared to an average 30-day volume of 622,000 shares. Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) is currently...

Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) traded today at a new 52-week high of $31.17. This new high was reached on above average trading volume as 9 million shares traded hands, while the average 30-day volume is approximately 672,000 shares. Cerevel Therapeutics Holdings Inc. (...

Cerevel Therapeutics Holdings, Inc. (CERE) Q2 2021 Earnings Conference Call August 11, 2021 08:00 ET Company Participants Matthew Calistri - Vice President of Investor Relations Tony Coles - Chairperson & Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renger - Chief Scie...

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2021 Q2 - Results - Earnings Call Presentation